Enzymes that Inactivate Vasoactive Peptides

  • E. G. Erdös
Part of the Handbook of Experimental Pharmacology / Handbuch der experimentellen Pharmakologie book series (HEP, volume 28 / 2)

Abstract

This chapter deals with the enzymatic inactivation of two types of vasoactive peptides, plasma kinins and angiotensin II. The metabolic fate of other hormonal or exogenous peptides is not discussed here.

Keywords

Hydrolysis Pancreatitis Proline Lysine Arginine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abdul-Karim, R., Assali, N.S.: Pressor response to angiotonin in pregnant and nonpregnant women. Amer. J. Obstet. Gynec. 82, 246–251 (1961).PubMedGoogle Scholar
  2. Abe, K., Watanabe, N., Kumagai, N., Miwa, I., Mouri, K., Seki, T., Oikawa, A., Yoshinaga, K.: Assay of kininase activity in human blood. Tohoku J. exp. Med. 86, 77–83 (1965).PubMedGoogle Scholar
  3. Abrams, J.S.: Blood pressure response to the portal infusion of angiotensin II. Surg. Forum 17, 133–134 (1966).PubMedGoogle Scholar
  4. Allwood, M.J., Lewis, G.P.: Bradykinin and forearm blood flow. J. Physiol. (Lond.) 170, 571–581 (1964).Google Scholar
  5. Amundsen, E., Nustad, K.: Kinin-forming and destroying activities of saliva. Brit. J. Pharmacol. 23, 440–444 (1964).PubMedGoogle Scholar
  6. Amundsen, E., Nustad, K.: Kinin-forming and destroying activities of cell homogenates. J. Physiol. (Lond.) 179, 479–88 (1965).Google Scholar
  7. Amundsen, E., Rugstad, H.E.: Influence of some pathogenic bacteria on kinin formation and destruction. Brit. J. Pharmacol. 25, 67–73 (1965).PubMedGoogle Scholar
  8. Arman, C.G. van, Nuss, G.W., Winter, C.A., Flataker, L.: Proteolytic enzymes as mediators of pain. In: Pharmacology of pain, p. 25. Ed. by R.K.S. Lim, D. Armstrong and E.G. Pardo. Oxford: Pergamon Press 1968.Google Scholar
  9. Armstrong, D., Stewart, J.W.: Spontaneous plasma kinin formation in human plasma collected during labour. Nature (Lond.) 188, 1193 (1960).Google Scholar
  10. Ascheim, R.S., Hammel, E.C., Mearles, R.J., Lubash, G.D.: Human serum, liver and kidney angiotensinases. Biochem. Med. 1, 288–294 (1967).Google Scholar
  11. Bakhle, Y.S.: Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature (Lond.) 220, 919–920 (1968).Google Scholar
  12. Bakhle, Y.S., Reynard, A.M., Vane, J.R.: Metabolism of the angiotensins in isolated perfused tissues. Nature (Lond.) 222, 956–959 (1969).Google Scholar
  13. Berger, M., Langhans, J.: Angiotensinase activity in pregnant and nonpregnant women. Amer. J. Obstet. Gynec. 98, 215–228 (1967).PubMedGoogle Scholar
  14. Beuzeville, C.A., Lauson, H.D.: Hepatic clearance of angiotensin from plasma of rats and dogs. Fed. Proc. 24, 524 (1965).Google Scholar
  15. Biron, P.: Les angiotensinase du plasma humain. Rev. Canad. Biol. 26, 43–53 (1967).PubMedGoogle Scholar
  16. Biron, P.: Pulmonary extraction of bradykinin and eledoisin. Rev. Canad. Biol. 27, 75–76 (1968).PubMedGoogle Scholar
  17. Biron, P., Baldus, W.P., Summerskill, W.H.J.: Plasma angiotensinase activity in cirrhosis. Proc. Soc. exp. Biol. (N.Y.) 116, 1074–1077 (1964b).Google Scholar
  18. Biron, P., Campeau, L., David, P.: Fate of angiotensin I and II in the human pulmonary circulation. Amer. J. Cardiol. 24, 544–547 (1969).PubMedGoogle Scholar
  19. Biron, P., Landesman, R., Hunt, J.C.: Plasma angiotensinase activity in human hypertension. Nature (Lond.) 204, 1096 (1964a).Google Scholar
  20. Biron, P., Meyer, P.: Hepatic extraction of angiotensin after carbon tetrachloride intoxication. Rev. Canad. Biol. 27, 277–279 (1968).PubMedGoogle Scholar
  21. Biron, P., Baldus, W.P., Panisset, J.-C.: Removal of angiotensins from the systemic circulation. Canad. J. Physiol. Pharmacol. 46, 175–178 (1968).Google Scholar
  22. Blaquier, P., Bohr, D.F., Taquini, A.C., Jr., Hoobler, S.W.: Renin and angiotensinase content of the kidney of normal and renal hypertensive rats. Proc. Soc. exp. Biol. (N.Y.) 108, 711–715 (1961).Google Scholar
  23. Boissonnas, R.A., Guttmann, St., Jaquenoud, P.-A.: Synthèse de la L-arginyl-L-prolyl-L-prolyl-glycyl-L-phenylalanyl-L-séryl-L-prolyl-L-phénylalanyl-L-arginine, un nonapetide présentant les proprietés de la bradykinine. Helv. chim. Acta 43, 1349–1358 (1960a).Google Scholar
  24. Boissonnas, R.A., Guttmann, St., Jaquenoud, P.-A.: Synthèse de la L-arginyl-L-prolyl-L-prolyl-glycyl-L-phenylalanyl-L-seryl-L-phenylalanyl-L-arginine. Distinction entre cet octapeptide et la bradykinine. Helv. chim. Acta 43, 1481–1487 (1960b).Google Scholar
  25. Bokisch, V.A., Müller-Eberhard, H.J.: Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J. exp. Med. (in press) (1970).Google Scholar
  26. Boucher, R., Veyrat, R., Champlatn, J. de, Genest, J.: New procedures for measurement of human plasma angiotensin and renin activity levels. Canad. med. Ass. J. 90, 194–201 (1964).PubMedGoogle Scholar
  27. Boyd, G.W., Landon, J., Peart, W.S.: Radioimmunoassay for determining plasma-levels of angiotensin II in man. Lancet 1967II, 1002–1005.Google Scholar
  28. Braun-Menéndez, E., Fasciolo, J.C., Leloir, L.F., Muñoz, J.M.: La substancia hipertensora de la sangre del reñón isquemiado. Rev. Soc. argent. Biol. 15, 420–425 (1939).Google Scholar
  29. Braun-Menéndez, E., Fasciolo, J.C., Leloir, L.F., Muñoz, J.M.: The substance causing renal hypertension. J. Physiol. (Lond.) 98, 283–298 (1940).Google Scholar
  30. Braun-Menéndez, E., Fasciolo, J.C., Leloir, L.F., Muñoz, J.M., Taquini, A.C.: Renal Hypertension. Springfield/Ill.: Charles C. Thomas 1946.Google Scholar
  31. Brunner, H.: Resistenz von verschiedenen Angiotensin-II-Isomeren gegen Inaktivierung durch Plasma oder Nierenhomogenat. Arch. exp. Path. 245, 283–284 (1963).Google Scholar
  32. Brunner, H., Regoli, D.: Unterschiedliche Empfindlichkeit verschiedener Angiotensinderivate gegen Abbau durch Plasma oder Nierenhomogenat. Experientia (Basel) 18, 504–505 (1962).Google Scholar
  33. Bumpus, F.M., Smeby, R.R., Page, I.H., Khairallah, P.A.: Distribution and metabolic fate of angiotensin II and various derivatives. Canad. med. Ass. J. 90, 190–193 (1964).PubMedGoogle Scholar
  34. Camargo, A.C.M., Graeff, F.G.: Subcellular distribution and properties of the bradykinin inactivation system in rabbit brain homogenates. Biochem. Pharmacol. 18, 548–549 (1969).PubMedGoogle Scholar
  35. Centaro, A., Periti, P., Sicuteri, F.: Bradykininogen and bradykininase in blood of women during labour. Settim. med. 51, Suppl. I, 70–76 (1963).Google Scholar
  36. Chamberlain, M.J., Browse, N.L., Gibson, D.G., Gleeson, J.A.: Angiotensin and renoportal anastomosis. Brit. med. J. 2, 1507–1508 (1964).PubMedGoogle Scholar
  37. Chesley, L.C., Talledo, E., Bohler, C.S., Zuspan, F.P.: Vascular reactivity to antiotensin II and norepinephrine in pregnant and nonpregnant women. Amer. J. Obstet. Gynec. 91, 837–842 (1965).PubMedGoogle Scholar
  38. Chiang, T.S., Erdös, E.G., Miwa, I., Tague, L.T., Coalson, J.J.: Isolation from a salivary gland of granules containing renin and kallikrein. Circulat. Res. 23, 507–517 (1968).PubMedGoogle Scholar
  39. Cohen, L.A., Gage, J.O., Kokame, G.M., Creech, O., Jr.: Hepatic inactivation of angiotensin. Bull. Tulane med. Fac. 26, 295–298 (1967).Google Scholar
  40. Croxatto, H.: La accion hipertensinasica; inactivacion de la hipertensina y de los principios presor y ocitocico de la posthipofisis en el organismo. Rev. Med. Aliment. (Santiago) 5, 259–271 (1943).Google Scholar
  41. Croxatto, H., Cruzatt, H.: Ineffectiveness of carboxypeptidase B in inhibiting the pressor effect of incubated human plasma. Experientia (Basel) 25, 59–60 (1969).Google Scholar
  42. Croxatto, R., Croxatto, H.: Comparative study of hypertensinase and proteinase activity of blood plasma. Proc. Soc. exp. Biol. (N.Y.) 61, 330–333 (1946).Google Scholar
  43. Cushman, D.W., Cheung, H.S.: A simple substrate for assay of dog lung angiotensin converting enzyme. Fed. Proc. 28, 799 (1969).Google Scholar
  44. Dahlheim, H., Petschauer, K., Thurau, K.: Anreicherung und Charakterisierung der Erythrocytenangiotensinase. Pflügers Arch. 305, 105–117 (1969).PubMedGoogle Scholar
  45. Dengler, H., Reichel, G.: Untersuchungen zur intrazellulären Localisation der Renin-und Hypertensinase-Aktivität. Experientia (Basel) 16, 36–40 (1960).Google Scholar
  46. Deutsch, H.F., Diniz, C.R.: Some proteolytic activities of snake venoms. J. biol. Chem. 216, 17–26 (1955).PubMedGoogle Scholar
  47. Dexter, L.: The hypertensinase content of plasma of normal, hypertensive and nephrectomized dogs. Ann. intern. Med. 17, 447–450 (1942).Google Scholar
  48. Dodson, L.F.: The pressor response to hypertensin in pregnant rats. Brit. J. exp. Path. 38, 635–639 (1957).PubMedGoogle Scholar
  49. Doyle, A.E., Louis, W.J., Osborn, E.C.: Plasma angiotensinase activity on angiotensin II and analogues. Aust. J. exp. Biol. med. Sci. 45, 41–50 (1967).PubMedGoogle Scholar
  50. Doyle, A.E., Louis, W.J., Jerums, G., Osborn, E.C.: Metabolism and blood levels following infusion of a radioactive analog of angiotensin. Amer. J. Physiol. 215, 164–168 (1968).PubMedGoogle Scholar
  51. Ebensperger, A., Croxatto, H.: Inactivacion de la hipertensina, de la vasopresina y de la ocitocina por los globulos blancos. Rev. Med. Aliment. (Santiago) 6, 243–246 (1945).Google Scholar
  52. Edery, H., Lewis, G.P.: Inhibition of plasma kininase activity at slightly acid pH. Brit. J. Pharmacol. 19, 299–305 (1962).PubMedGoogle Scholar
  53. Effkemann, G., Werle, E.: Die körpereigenen uteruswirksamen und kreislaufaktiven Wirkstoffe im Schwangerenorganismus. Arch. Gynäk. 171, 1–27 (1941).Google Scholar
  54. Elliott, D.F., Lewis, G.P.: Methionyl-lysyl-bradykinin, a new kinin from ox blood. Biochem. J. 95, 437–447 (1965).PubMedGoogle Scholar
  55. Elliott, D.F., Lewis, G.P., Horton, E.W.: The structure of bradykinin — a plasma kinin from ox blood. Biochem. biophys. Res. Commun. 3, 87–91 (1960).Google Scholar
  56. Enomoto, T., Mineshita, S., Oh-Ishi, S., Shigei, T.: Kininase activity of stem bromelain. Jap. J. Pharmacol. 17, 331–332 (1967).PubMedGoogle Scholar
  57. Erdös, E.G.: Enzymes that inactive active polypeptides. Biochem. Pharmacol. 8, 112 (1961).Google Scholar
  58. Erdös, E.G.: Enzymes that inactivate polypeptides. In: Metabolic factors controlling duration of drug actions, pp. 159–178. Ed. by B.B. Brodie and E.G. Erdös. Oxford: Pergamon Press 1962.Google Scholar
  59. Erdös, E.G.: Hypontensive peptides, bradykinin, kallidin and eledoisin. Advanc. Pharmacol. 4, 1–90 (1966).Google Scholar
  60. Erdös, E.G., Cano, G., Yang, H.Y.T.: Hypotensive effect of Lys9-bradykinin in the guinea pig. Biochem. Pharmacol. 16, 1035–1041 (1967c).PubMedGoogle Scholar
  61. Erdös, E.G., McMennamin, M.A., Wohler, J.R.: Presence of carboxypeptidase B in crude kallikrein (Padutin) preparations. Life Sci. 1, 765–769 (1962).Google Scholar
  62. Erdös, E.G., Miwa, I.: Effect of endotoxin shock on the plasma kallikrein-kinin system of the rabbit. Fed. Proc. 27, 92–95 (1968).PubMedGoogle Scholar
  63. Erdös, E.G., Miwa, I., Graham, W.J.: Studies on the evolution of plasma kinins. Kinins of reptilian and avian blood. Life Sci. 6, 2433–2439 (1967b).Google Scholar
  64. Erdös, E.G., Renfrew, A.G., Sloane, E.M., Wohler, J.R.: Enzymatic studies on bradykinin and similar peptides. Ann. N.Y. Acad. Sci. 104, 222–234 (1963b).Google Scholar
  65. Erdös, E.G., Seki, T., Yang, H.Y.T., Tague, L.L.: Use of insoluble polymers of enzymes in kinin metabolism. Pharmacol. Res. Commun. 1, 152 (1969).Google Scholar
  66. Erdös, E.G., Sloane, E.M.: An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem. Pharmacol. 11, 585–592 (1962).PubMedGoogle Scholar
  67. Erdös, E.G., Sloane, E.M., Wohler, I.M.: Carboxypeptidase in blood and other fluids. I. Properties, distribution and partial purification of the enzyme. Biochem. Pharmacol. 13, 893–905 (1964).Google Scholar
  68. Erdös, E.G., Wohler, I.M., Levine, M.I., Westerman, M.P.: Carboxypeptidase in blood and other fluids. Values in human blood in normal and pathological conditions. Clin. chim. Acta 11, 39–43 (1965).Google Scholar
  69. Erdös, E.G., Wohler, J.R.: Inhibitors of the in vivo enzymatic inactivation of bradykinin and kallidin. Life Sci. 2, 270–274 (1963a).Google Scholar
  70. Erdös, E.G., Wohler, J.R.: Inhibition in vivo of the enzymatic inactivation of bradykinin and kallidin. Biochem. Pharmacol. 12, 1193–1199 (1963b).Google Scholar
  71. Erdös, E.G., Wohler, J.R., Levine, M.I.: Blocking of the in vivo effects of bradykinin and kallidin with carboxypeptidase B. J. Pharmacol. exp. Ther. 142, 327–334 (1963a).Google Scholar
  72. Erdös, E.G., Yang, H.Y.T.: Inactivation and potentiation of the effects of bradykinin. In: Hypotensive peptides, pp. 235–250. Ed. by E.G. Erdös, N. Back and F. Sicuteri. Berlin-Heidelberg-New York: Springer 1966.Google Scholar
  73. Erdös, E.G., Yang, H.Y.T.: An enzyme in microsomal fraction of kidney that inactivates bradykinin. Life Sci. 6, 569–574 (1967).PubMedGoogle Scholar
  74. Erdös, E.G., Yang, H.Y.T.: Kininases. In: Bradykinin, kallidin and kallikrein, Handbook of Experimental Pharmacology, p. 289. Ed. by E.G. Erdös. Berlin-Heidelberg-New York: Springer 1970.Google Scholar
  75. Erdös, E.G., Yang, H.Y.T., Miwa, I.: Kininases. Hoppe-Seylers Z. physiol. Chem. 349, 928 (1968).PubMedGoogle Scholar
  76. Erdös, E.G., Yang, H.Y.T., Tague, L.L., Manning, N.: Carboxypeptidase in blood and other fluids. III. The esterase activity of the enzyme. Biochem. Pharmacol. 16, 1287–1297 (1967a).PubMedGoogle Scholar
  77. Fasciolo, J.C.: Formation and destruction of plasma kinins. Acta physiol. lat.-amer. 14, 170–179 (1964).PubMedGoogle Scholar
  78. Fasciolo, J.C., Leloir, L.F., Muñoz, J.M., Braun-Menéndez, E.: La hipertensinasa: Su dosaje y distributión. Rev. Soc. argent. Biol. 16, 643–649 (1940).Google Scholar
  79. Ferreira, S.H.: Bradykinin-potentiating factor. In: Hypotensive peptides, pp. 356–367. Ed. by E.G. Erdös, N. Back and F. Sicuteri. Berlin-Heidelberg-New York: Springer 1966.Google Scholar
  80. Ferreira, S.H., Vane, J.R.: The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Brit. J. Pharmacol. 30, 417–424 (1967a).PubMedGoogle Scholar
  81. Ferreira, S.H., Vane, J.R.: The detection and estimation of bradykinin in the circulating blood. Brit. J. Pharmacol. 29, 367–377 (1967b).PubMedGoogle Scholar
  82. Folk, J.E., Piez, K.A., Carroll, W.R., Gladner, J.A.: Carboxypeptidase B. IV. Purification and characterization of the porcine enzyme. J. biol. Chem. 235, 2272–2277 (1960).PubMedGoogle Scholar
  83. Frey, E.K., Kraut, H., Werle, E.: Kallikrein Padutin. Stuttgart: Ferdinand Enke 1950.Google Scholar
  84. Frey, E.K., Kraut, H., Werle, E., Vogel, R., Zickgraf-Rüdel, G., Trautschold, I.: Das Kallikrein-Kinin-System und seine Inhibitoren. Stuttgart: Ferdinand Enke 1968.Google Scholar
  85. Garbe, G.: Quantitative Kininogenbestimmung in menschlichem Plasma. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 256, 112–118 (1967).Google Scholar
  86. Glenner, G.G., McMillan, P.J., Folk, J.E.: A mammalian peptidase specific for the hydrolysis of N-terminal and α-L-glutamyl and aspartyl residues. Nature (Lond.) 194, 867 (1962).Google Scholar
  87. Goffinet, J.A., Mulrow, P.J.: Estimation of angiotensin clearance by an in vivo assay. Clin. Res. 11, 408 (1963).Google Scholar
  88. Goldacker, I.U. v., Oelkers, W.: Aminopeptidaseaktivität gegen Angiotensin II-Amid im Serum von Gesunden, Schwangeren, Hypertonikern und Leberkranken. Z. klin. Chem. u. klin. Biochem. 7, 250–252 (1969).Google Scholar
  89. Gollan, F., Richardson, E., Goldblatt, H.: Studies on plant hypertensinase. J. exp. Med. 87, 29–39 (1948).PubMedGoogle Scholar
  90. Greenbaum, L.M., Kim, K.S.: The kinin-forming and kininase activities of rabbit polymorphonuclear leucocytes. Brit. J. Pharmacol. 29, 238–247 (1967).PubMedGoogle Scholar
  91. Greenbaum, L.M., Yamafuji, K.: The in vitro inactivation and formation of plasma kinins by spleen cathepsins. Brit. J. Pharmacol. 27, 230–238 (1966).PubMedGoogle Scholar
  92. Greene, L.J., Stewart, J.M., Ferreira, S.H.: Bradykinin-potentiating peptides from the venom of Bothrops jararaca. Advanc. exp. Med. Biol. 8, 81–87 (1970).Google Scholar
  93. Haas, E., Goldblatt, H., Lewis, L., Gipson, E.C.: Inhibition of angiotensin and its protection by a cofactor in blood. Amer. J. Physiol. 215, 1420–1428 (1968).PubMedGoogle Scholar
  94. Haas, E., Goldblatt, H., Lewis, L., Gipson, E.C.: Angiotensin-protective cofactor. Amer. J. Physiol. 217, 981–987 (1969).PubMedGoogle Scholar
  95. Haber, E., Koerner, T., Page, L.B., Kliman, B., Purnode, A.: Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J. clin. Endocr. 29, 1349–1355 (1969).PubMedGoogle Scholar
  96. Habermann, E., Blennemann, G.: Über Substrate und Reaktionsprodukte der kininbildenden Enzyme Trypsin, Serum-und Pankreaskallikrein sowie von Crotalusgift. Arch. exp. Pathol. Pharmakol. 249, 357–373 (1964).Google Scholar
  97. Hamberg, U., Rocha e Silva, M.: Studies on the enzymatic inactivation of bradykinin. Acta physiol. scand. 30, 215–225 (1954).PubMedGoogle Scholar
  98. Hamberg, U., Rocha e Silva, M.: On the release of bradykinin by trypsin and snake venoms. Arch. int. Pharmacodyn. 110, 222–238 (1957).PubMedGoogle Scholar
  99. Harakal, C.D., Collins, D.A.: Plasma hypertensinase in experimental renal hypertension. Circulat. Res. 4, 612–617 (1956).PubMedGoogle Scholar
  100. Hess, R.: Arylamidase activity related to angiotensinase. Biochim. biophys. Acta (Amst.) 99, 316–324 (1965).Google Scholar
  101. Hickler, R.B., Lauler, D.P., Thorn, G.W.: Plasma angiotensinase activity in patients with hypertension and edema. J. clin. Invest. 42, 635–648 (1963).PubMedGoogle Scholar
  102. Hiwada, K.: Studies on plasma angiotensinases in liver disease. Jap. Circulat. J. 32, 1073–1083 (1968).Google Scholar
  103. Hiwada, K., Akutsu, H., Fujimoto, S., Kokubu, T., Yamamura, Y.: Separation of plasma angiotensinases by DEAE Sephadex A-50 column chromatography. Clin. chim. Acta 14, 410–441 (1966).PubMedGoogle Scholar
  104. Hodge, R.L., Ng, K.K.F., Vane, J.R.: Disappearance of angiotensin from the circulation of the dog. Nature (Lond.) 215, 138–141 (1967).Google Scholar
  105. Hooper, K.C.: The enzymic inactivation of some physiologically active polypeptides by different parts of the nervous system. Biochem. J. 88, 398–404 (1963).PubMedGoogle Scholar
  106. Hopsu, V.K., Makinen, K.K., Glenner, G.G.: A peptidase (aminopeptidase B) from cat and guinea pig liver selective for N-terminal arginine and lysine residues. I. Purification and substrate specificity. Acta chem. scand. 20, 1225–1230 (1966a).PubMedGoogle Scholar
  107. Hopsu, V.K., Makinen, K.K., Glenner, G.G.: Formation of bradykinin from kallidin-10 by aminopeptidase B. Nature (Lond.) 212, 1271–1272 (1966b).Google Scholar
  108. Horton, E.W.: The estimation of urinary kallikrein. J. Physiol. (Lond.) 148, 267–282 (1959).Google Scholar
  109. Itskovitz, H.D., Dudrick, S.J., Dyrda, I., Murphy, J.J.: Plasma angiotensinase activity in hypertensive patients. Arch. intern. Med. 119, 241–246 (1967).PubMedGoogle Scholar
  110. Itskovitz, H.D., Miller, L.D.: Renal angiotensinase activity. Circulat. Res. 19, 507–513 (1966).PubMedGoogle Scholar
  111. Itskovitz, H.D., Miller, L.D.: Differential studies of angiotensinase activities from several tissue sources. Amer. J. med. Sci. 254, 659–666 (1967).PubMedGoogle Scholar
  112. Itskovitz, H.D., Miller, L.D., Ural, W., Zapp, J., White, R.: Inactivation of angiotensin in shock. Amer. J. Physiol. 216, 5–10 (1969).PubMedGoogle Scholar
  113. Johnson, D.C., Ryan, J.W.: Degradation of angiotensin II by a carboxypeptidase of rabbit liver. Biochim. biophys. Acta (Amst.) 160, 196–203 (1968).Google Scholar
  114. Kelly, K.A., Nyhus, L.M.: Angiotensin and the liver. Amer. J. Physiol. 210, 305–311 (1966).PubMedGoogle Scholar
  115. Kemp, E., Rubin, I.: Removal of angiotensinase from a preparation of renin. Arch. Biochem. Biophys. 96, 56–59 (1962).PubMedGoogle Scholar
  116. Khairallah, P.A., Bumpus, F.M., Page, I.H., Smeby, R.R.: Angiotensinase with a high degree of specificity in plasma and red cells. Science 140, 672–674 (1963).PubMedGoogle Scholar
  117. Khairallah, P.A., Page, I.H. Plasma angiotensinases. Biochem. Med. 1, 1–8 (1967).Google Scholar
  118. Khairallah, P.A., Page, I.H., Bumpus, F.M., Smeby, R.R.: Angiotensin II: Its metabolic fate. Science 138, 523–525 (1962).PubMedGoogle Scholar
  119. Khairallah, P.A., Page, I.H., Bumpus, F.M., Türker, R.K.: Angiotensin tachyphylaxis and its reversal. Circulat. Res. 19, 247–254 (1966).PubMedGoogle Scholar
  120. Klaus, D.: Untersuchungen über die Angiotensinase im Serum Gesunder und Kranker. Klin. Wschr. 40, 701–702 (1962).PubMedGoogle Scholar
  121. Klaus, D.: Vergleichende Untersuchungen über die Blutdruckwirkung von α-und β-Angiotensin II bei intravenöser Infusion. Klin. Wschr. 44, 1044–1046 (1966).PubMedGoogle Scholar
  122. Klaus, D., Daum, A.: Die Wirkung von Aminopeptidase auf den experimentellen renalen Hochdruck der Ratte. Klin. Wschr. 44, 903–904 (1966).PubMedGoogle Scholar
  123. Klaus, D., Heizmann, A., Uehleke, H.: Beeinflussung der Blutdruckwirkung von Angiotensin durch Aminopeptidasen und Carboxypeptidase. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 251, 28–38 (1965).Google Scholar
  124. Klaus, D., Kaffarnik, H., Pfeil, H.: Untersuchungen über die Serum-Angiotensinase I, II. Klin. Wschr. 41, 376–385 (1963).PubMedGoogle Scholar
  125. Kleine, R., Tille, D.: Charakterisierung der Protamin hydrolysierenden Enzymwirkung des Rattenserums. Acta biol. med. germ. 22, 525–535 (1969).PubMedGoogle Scholar
  126. Kokubu, T.: Renal hypertension and angiotensinase. Jap. J. Med. 5, 102–104 (1966).Google Scholar
  127. Kokubu, T., Akutsu, H., Fujimoto, S., Ueda, E., Hiwada, K., Yamamura, Y.: Purification and properties of endopeptidase from rabbit red cells and its process of degradation of angiotensin. Biochim. biophys. Acta (Amst.) 191, 668–676 (1969).Google Scholar
  128. Kokubu, T., Fujimoto, S., Hiwada, K., Akutsu, H., Kato, A., Yamamura, Y.: Inactivation of angiotensin II in liver. Jap. Circulat. J. 31, 879–883 (1967a).Google Scholar
  129. Kokubu, T., Hiwada, K., Ueda, E., Fujimoto, S., Akutsu, H., Kato, A., Yamamura, Y.: Plasma angiotensinase activity in liver disease. Biochem. Med. 1, 54–61 (1967b).Google Scholar
  130. Krivoy, W., Kroger, D.: The preservation of bradykinin by phenothiazines in vitro. Brit. J. Pharmacol. 22, 329–341 (1964).PubMedGoogle Scholar
  131. Kroneberg, G., Stoepel, K.: Vergleichende Untersuchungen über die Kreislaufwirkung von Kallikrein (Padutin), Kallidin und Bradykinin. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 245, 284–285 (1963).Google Scholar
  132. Kurtz, A.B., Wachsmuth, E.D.: Identification of plasma angiotensinase as aminopeptidase. Nature (Lond.) 221, 92–93 (1969).Google Scholar
  133. Lagrue, G., Meyer, P.: Dosage biologique de l’angiotensinase plasmatique. Technique et premiers résultats. Path. et Biol. 11, 895–897 (1963).Google Scholar
  134. Landesman, R., Biron, P., Castellanos, R., Russa, R.L., Wilson, K.H.: Plasma angiotensinase activity in normal and toxemic pregnancy. Obstet. and Gynec. 22, 316–323 (1963).Google Scholar
  135. Leary, W.P., Ledingham, J.G.: Removal of angiotensin by isolated perfused organs of the rat. Nature (Lond.) 222, 959–960 (1969).Google Scholar
  136. Levin, Y., Pecht, M., Goldstein, L., Katchalski, E.: A water-insoluble polyanionic derivative of trypsin. I. Preparation and properties. Biochemistry 3, 1905–1913 (1964).PubMedGoogle Scholar
  137. Loyke, H.F.: Experimental hypertensions treated with CCl4: Measurements of Adrenal Function, Vascular Responsiveness, Angiotensinase and Converting Enzyme. Proc. Soc. exp. Biol. (N.Y.) 115, 1035–1040 (1964).Google Scholar
  138. Lubash, G.D., Bard, R.H., Kline, J.A.: Serum “angiotensinase activity” and female steroidal hormones. Amer. J. med. Sci. 257, 155–163 (1969).PubMedGoogle Scholar
  139. Lubash, G.D., Hammel, E.C., Mearles, R.J.: Serum angiotensinase activity in hypertension. Clin. chim. Acta 18, 439–445 (1967).Google Scholar
  140. Lubash, G.D., Hammel, E.C., Mearles, R.J.: Serum angiotensinase activity in cirrhosis. Amer. J. med. Sci. 255, 105–112 (1968).PubMedGoogle Scholar
  141. Manca, P., Morandini, G., Mangioni, C., Dimich, D.: L’attività angiotensinasica plasmatica nel corso della gravidanza normale e del puerperio. Minerva ginec. 19, 319–324 (1967).PubMedGoogle Scholar
  142. Margolis, J., Bishop, E.A.: Interrelations between different mechanisms of release of biologically active peptides from blood plasma. Nature (Lond.) 194, 749–751 (1962).Google Scholar
  143. Matsunaga, M., Kira, J., Saito, N., Ogino, K., Takayasu, M.: Acid angiotensinase, renin, and acid adenosine triphosphatase in rat kidney lysosomes. Jap. Circulat. J. 32, 137–143 (1968).Google Scholar
  144. Matsunaga, M., Saito, N., Kira, J., Ogino, K., Takayasu, M.: Acid angiotensinase as a lysosomal enzyme. Jap. Circulat. J. 33, 541–551 (1969).Google Scholar
  145. McCarthy, D.A., Potter, D.E., Nicolaides, E.D.: An in vivo estimation of the potencies and half-lives of synthetic bradykinin and kallidin. J. Pharmacol. exp. Ther. 148, 117–122 (1965).PubMedGoogle Scholar
  146. McDonald, J.K., Zeitman, B.B., Reilly, T.J., Ellis, S.: New observations on the substrate specificity of cathepsin C (dipeptidyl aminopeptidase I). J. biol. Chem. 244, 2693–2709 (1969).PubMedGoogle Scholar
  147. McDonald, J.K., Callahan, P.X., Ellis, S.: Polypeptide degradation by dipeptidyl aminopeptidase I (cathepsin C) and related peptidases. In: Tissue Proteinases: Enzymology and Biology. Ed. by A.J. Barrett, J.T. Dingle, Amsterdam: North-Holland Publishing Co. (in press).Google Scholar
  148. Melmon, K.L., Cline, M.J.: Interaction of plasma kinins and granulocytes. Nature (Lond.) 217, 90–92 (1967).Google Scholar
  149. Melmon, K.L., Cline, M.J.: The interaction of leukocytes and the kinin system. Biochem. Pharmacol. 17, Suppl., p. 271–281 (1968).Google Scholar
  150. Melmon, K.L., Cline, M.J., Hughes, T., Nies, A.S.: Kinins: possible mediators of neonatal circulatory changes in man. J. clin. Invest. 47, 1295–1302 (1968).PubMedGoogle Scholar
  151. Methot, A.L., Meyer, P., Biron, P., Lorain, M.P., Lagrue, G., Milliez, P.: Hepatic inactivation of angiotensin. Nature (Lond.) 203, 531–532 (1964).Google Scholar
  152. Mitchell, W.M.: Hydrolysis at arginylproline in polypeptides by clostridiopeptidase B. Science 162, 374–375 (1968).PubMedGoogle Scholar
  153. Miwa, I., Erdös, E.G., Seki, T.: Separation of peptide components of urinary kinin (Substance Z). Proc. Soc. exp. Biol. (N.Y.) 131, 768–772 (1969).Google Scholar
  154. Morris, R.E.: In discussion. Canad. med. Ass. J. 90, 194 (1964).Google Scholar
  155. Myers, M.G., Robinson, P.R., Morris, R.E.: Relationships of angiotensinase and angiotensin II. Clin. Res. 13, 215 (1965).Google Scholar
  156. Nagatsu, I., Gillespie, L., Folk, J.E., Glenner, G.G.: Serum aminopeptidases, “angiotensinase”, and hypertension. I. Degradation of angiotensin II by human serum. Biochem. Pharmacol. 14, 721–728 (1965a).PubMedGoogle Scholar
  157. Nagatsu, I., Gillespie, L., George, J.M., Folk, J.E., Glenner, G.G.: Serum aminopeptidases, “angiotensinase”, and hypertension. II. Amino acid β-naphthylamide hydrolysis by normal and hypertensive serum. Biochem. Pharmacol. 14, 853–861 (1965b).PubMedGoogle Scholar
  158. Nagatsu, I., Nagatsu, T., Yamamoto, T., Glenner, G.G., Mehl, J.W.: Purification of aminopeptidase A in human serum and degradation of angiotensin II by the purified enzyme. Biochim. biophys. Acta (Amst.) 198, 255–270 (1970).Google Scholar
  159. Nicolaides, E.D., Dewald, H.A., Craft, M.K.: The synthesis of kinin analogues. Ann. N.Y. Acad. Sci. 104, 15–22 (1963).PubMedGoogle Scholar
  160. Nishimura, H., Sokabe, H.: Inhibition of angiotensinases in the rat plasma and kidney. Jap. Heart J. 9, 494–503 (1968).PubMedGoogle Scholar
  161. Nugent, F.W., Atendido, W.A., Bulan, M.B., MacDonald, A.J.: Kininase activity in experimental pancreatitis. Nature (Lond.) 211, 207–208 (1966).Google Scholar
  162. Oelkers, W., Goldacker, I.U. v.: Bestimmung der Angiotensinase(Aminopeptidase-)-Aktivität im Serum mit einem DPN-abhängigen optischen Test. Klin. Wschr. 45, 649–653 (1967).PubMedGoogle Scholar
  163. Ono, T., Eto, K., Arakawa, K.: Origin of urinary enzymes hydrolysing β-naphthylamides of L-leucine and L-glutamic acid. Clin. chim. Acta 19, 257–265 (1968).PubMedGoogle Scholar
  164. Osborn, E.C., Hughes, S.G., Pirie, A.T., Willicombe, P.R., Mahler, R.F.: Clearance studies of angiotensin II and (35S) phenylthiocarbamyl-angiotensin II in the sheep and dog. Cardiovasc. Res. 3, 134–146 (1969).Google Scholar
  165. Osborn, E.C., Jerums, G., Jupp, B.A.: Plasma angiotensinase activity in relation to the breakdown of phenylthiocarbamyl-angiotensin II amide in hypertensive and normotensive patients. Cardiovasc. Res. 2, 31–32 (1968a).PubMedGoogle Scholar
  166. Osborn, E.C., Jerums, G., Jupp, B.A.: Blood angiotensinase activity in relation to the breakdown of angiotensin II amide and nonisotopic phenylthiocarbamyl-angiotensin II amide in hypertensive and normotensive patients. Cardiovasc. Res. 2, 33–38 (1968b).PubMedGoogle Scholar
  167. Osborne, M.J., d’Auriac, G.A., Meyer, P., Worcel, M.: Mechanism of Extraction of Angiotensin II in coronary and renal circulations. Life Sci. 9, 859–867 (1970).Google Scholar
  168. Page, I.H., Helmer, O.M.: A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator. J. exp. Med. 71, 29–42 (1940).PubMedGoogle Scholar
  169. Page, I.H., Helmer, O.M., Kohlstaedt, K.G., Kempf, G.F., Corcoran, A.C., Taylor, R.D.: A progress report on investigations concerned with the experimental treatment of hypertension with kidney extracts. Ann. intern. Med. 18, 29–42 (1943).Google Scholar
  170. Page, I.H., McCubbin, J.W., editors: Renal Hypertension. Chicago: Year Book Medical Publishers, Inc. 1968.Google Scholar
  171. Paskhina, T.S., Trapeznikova, S.S.: Cleavage of depsipeptide analogs of bradykinin by kininase (carboxypeptidase N) from human and rabbit serum. Biokhimiya 32, 527 (1967).Google Scholar
  172. Phelps, P., Prockhop, D.J., McCarty, D.J.: Crystal induced inflammation in canine joints. III. Evidence against bradykinin as a mediator of inflammation. J. Lab. clin. Med. 68, 433–444 (1966).PubMedGoogle Scholar
  173. Pickens, P.T., Bumpus, F.M., Lloyd, A.M., Smeby, R.R., Page, I.H.: Measurement of renin activity in human plasma. Circulat. Res. 17, 438–448 (1965).PubMedGoogle Scholar
  174. Prado, J.L.: Proteolytic enzymes as kininogenases. In: “Bradykinin, kallidin and kallikrein”, Handbook of Experimental Pharmacology, p. 156. Ed. by E.G. Erdös. Berlin-Heidelberg-New York: Springer 1970.Google Scholar
  175. Regoli, D., Riniker, B., Brunner, H.: The enzymatic degradation of various angiotensin II derivatives by serum, plasma or kidney homogenate. Biochem. Pharmacol. 12, 637–646 (1963).PubMedGoogle Scholar
  176. Riniker, B.: Recent work on the chemistry and biochemistry of angiotensin II. Metabolism 13, 283–291 (1964).Google Scholar
  177. Riniker, B., Schwyzer, R.: Die sterische Einheitlichkeit des synthetischen Val5-Hypertensin II-Asp1-β-amids. Helv. chim. Acta 44, 658–667 (1961).Google Scholar
  178. Riniker, B., Schwyzer, R.: Synthetische Analoge des Hypertensins. V. α-L-, β-L-, α-D-und β-D-Asp1-Val5-Hypertensin II; Desamino-Val5-Hypertensin II. Helv. chim. Acta 47, 2357–2374 (1964).Google Scholar
  179. Rocha e Silva, M.: Bradykinin — mechanism of its release by trypsin and kallikrein. Arch. int. Pharmacodyn. 88, 271–282 (1951).Google Scholar
  180. Rocha e Silva, M.: The physiological significance of bradykinin. Ann. N.Y. Acad. Sci. 104, 190–210 (1963).Google Scholar
  181. Rocha e Silva, M., Beraldo, W.T., Rosenfeld, G.: Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Amer. J. Physiol. 156, 261–273 (1949).PubMedGoogle Scholar
  182. Rugstad, H.E.: Kininase production by some microbes. Brit. J. Pharmacol. 28, 315–323 (1966).PubMedGoogle Scholar
  183. Rugstad, H.E.: Purification of a kinin-inactivating enzyme from cultures of Pseudomonas aeruginosa. Brit. J. Pharmacol. 30, 134–142 (1967a).PubMedGoogle Scholar
  184. Rugstad, H.E.: Characterization of a plasma kinin-inactivating enzyme produced by Pseudomonas aeruginosa. Brit. J. Pharmacol. 30, 425–435 (1967b).PubMedGoogle Scholar
  185. Rugstad, H.E.: Degradation of plasma kinins by an enzyme from Pseudomonas aeruginosa. Brit. J. Pharmacol. 31, 401–406 (1967c).PubMedGoogle Scholar
  186. Ryan, J.W., Roblero, J., Stewart, J.M.: Inactivation of bradykinin in the pulmonary circulation. Biochem. J. 110, 795–797 (1968a).PubMedGoogle Scholar
  187. Ryan, J.W., McKenzie, J.K., Lee, M.R.: A rapid simple method for the assay of renin in rabbit plasma. Biochem. J. 108, 679–685 (1968b).PubMedGoogle Scholar
  188. Saameli, K., Eskes, T.K.A.B.: Bradykinin and cardiovascular system: estimation of half-life. Amer. J. Physiol. 203, 261–265 (1962).PubMedGoogle Scholar
  189. Saito, N., Sanada, K., Matsunaga, M., Kira, J., Mukaino, S., Ogino, K., Takayasu, M.: Amino acid analysis after degradation of angiotensin II by rat kidney lysosomes. Jap. Circulat. J. 33, 87–93 (1969).Google Scholar
  190. Sambhi, M.P., Barrett, J.D.: Angiotensinase activity in fractionated human plasma and effect of enzyme inhibitors. Clin. Res. 14, 149 (1966).Google Scholar
  191. Sambhi, M.P., Barrett, J.D.: Plasma “angiotensinase” activity as a determinant of angiotensin pressor action and tachyphylaxis in the rat. Biochem. Pharmacol. 17, 787–795 (1968).PubMedGoogle Scholar
  192. Sapirstein, L.A., Reed, R.K., Page, E.W.: The site of angiotonin destruction. J. exp. Med. 83, 425–439 (1946).Google Scholar
  193. Schachter, M.: Some properties of kallidin, bradykinin and wasp venom kinin. In: Polypeptides which affect smooth muscles and blood vessels, pp. 232–246. Ed. by M. Schachter. Oxford 1960.Google Scholar
  194. Schröder, E.: Über Peptidsynthesen. Synthese von Methionyl-Lysyl-Bradykinin, einem Kinin aus Rinderblut. Experientia (Basel) 20, 39 (1964).Google Scholar
  195. Schröder, E., Lübke, K.: The Peptides. Vol. II. New York: Academic Press 1966.Google Scholar
  196. Schwab, J.: Kininases in leucocytes and other tissues. Nature (Lond.) 195, 345–347 (1962).Google Scholar
  197. Seki, I., Jenssen, T.A., Levin, Y., Erdös, E.G.: Active water-insoluble derivative of renin. Nature (Lond.) 225, 864–865 (1970b).Google Scholar
  198. Seki, I., Yang, H.Y.T., Levin, Y., Jenssen, T.A., Erdös, E.G.: Application of water-insoluble complexes of kininogenases, inhibitors and kininases to kinin research. Advanc. exp. Med. Biol. (in press) (1970a).Google Scholar
  199. Shimonaeva, E.E.: Some properties of carboxypeptidase N from rabbit blood serum. Vop. med. Khim 13, 105–107 (1967).Google Scholar
  200. Sicuteri, P., Fanciullacci, M., Del Bianco, P.L., Anselmi, B.: Bradichininasi nel liquido cefalo-rachidiano dell-uomo. Boll. Soc. ital. Biol. sper. 41, 464–466 (1965).PubMedGoogle Scholar
  201. Sicuteri, P., Periti, P., Anselmi, B., Fanciullacci, M.: Livelli plasmachininici dell’uomo dopo somministrazione endovenosa ed endoarteria di bradichinina sintetica e naturale. Boll. Soc. ital. Biol. sper. 39, 314–318 (1963).PubMedGoogle Scholar
  202. Skeggs, L.T., Lentz, K.E., Kahn, J.R., Dorer, F.E., Levine, M.: Pseudorenin; a new angiotensin-forming enzyme. Circulat. Res. 25, 451–462 (1969).PubMedGoogle Scholar
  203. Stewart, J.M.: Synthesis and pharmacology of polistes kinin, a bradykinin homolog. Fed. Proc. 27, 534 (1968).Google Scholar
  204. Stewart, J.M., Roblero, J.: Studies on the pulmonary inactivation of bradykinin. In: Symposium on Vasoactive Polypeptides and Inhibitors of Proteolytic Enzymes, pp. 52–55. Tokyo 1967.Google Scholar
  205. Suzuki, T., Iwanaga, S.: Snake venoms. In: Bradykinin, kallidin and kallikrein, Handbook of Experimental Pharmacology, p. 193. Ed. by E.G. Erdös. Berlin-Heidelberg-New York: Springer 1970.Google Scholar
  206. Suzuki, T., Iwanaga, S., Nagasawa, S., Sato, T.: Purification and properties of bradykininogen and of the bradykinin-releasing and-destroying enzymes in snake venom. In: Hypotensive peptides, pp. 149–160. Ed. by E.G. Erdos, N. Back and F. Sicuteri. Berlin-Heidelberg-New York: Springer 1966.Google Scholar
  207. Talledo, O.: Renin-angiotensin system in normal and toxemic pregnancies. II. Inactivation of angiotensin in normal pregnancy. Amer. J. Obstet. Gynec. 97, 571–572 (1967).PubMedGoogle Scholar
  208. Teger-Nilsson, A.-C.: Degradation of human fibrinopeptides A and B in blood serum in vitro. Acta chem. scand. 22, 3171–3182 (1968).PubMedGoogle Scholar
  209. Trapeznikova, S.S., Paskhina, T.S.: The isolation, purification and properties of carboxypeptidases (kininases) from human and rabbit blood serum. Biokhimiya 33, 1012–1022 (1968).Google Scholar
  210. Trautschold, I.: Enzyme und Inhibitoren der Bildung und des Abbaues gefäßaktiver Polypeptide (Kinine). Habil.-Schrift Munich 1965.Google Scholar
  211. Urbanitz, D., Wiegand, H., Habermann, E.: Zur Frage der Bedeutung des Kininsystems beim thermischen Odem der Rattenpfote. Naunyn-Schmiedeberg’s Arch. 264, 476–493 (1969).Google Scholar
  212. Vane, J.R.: The release and rate of vasoactive hormones in the circulation. Brit. J. Pharmacol. 35, 209–242 (1969).Google Scholar
  213. Vorherr, H., Dimitrow, A., Hüter, J.: Biologische Untersuchungen über den Abbau von Hypertensin durch Blutplasma von nichtschwangeren und schwangeren Frauen. Klin. Wschr. 43, 614–617 (1965).PubMedGoogle Scholar
  214. Watanabe, N.: Kininase activity in human blood in normal and pathological conditions. Tohoku J. exp. Med. 92, 63–72 (1967).PubMedGoogle Scholar
  215. Watanabe, N., Abe, K., Kumagai, N., Mouri, T., Seki, T., Yoshinaga, K.: Kininase activity in human blood. Tohoku J. exp. Med. 89, 383–386 (1966).PubMedGoogle Scholar
  216. Webster, M.E.: Report of the committee on nomenclature for hypotensive peptides. In: Hypotensive Peptides, pp. 648–653. Ed. by E.G. Erdös, N. Back and F. Sicuteri. Berlin-Heidelberg-New York: Springer 1966.Google Scholar
  217. Webster, M.E., Pierce, J.V.: The nature of the kallidins released from human plasma by kallikreins and other enzymes. Ann. N.Y. Acad. Sci. 104, 91–105 (1963).PubMedGoogle Scholar
  218. Webster, M.E., Skinner, N.S., Jr., Powell, W.J., Jr.: Role of the kinins in vasodilatation of skeletal muscle of the dog. Amer. J. Physiol. 212, 553–558 (1967)PubMedGoogle Scholar
  219. Werle, E.: Über Kallidin und Bradykinin. Arch. int. Pharmacodyn. 92, 427–431 (1953).PubMedGoogle Scholar
  220. Werle, E.: Kallikrein, kallidin and related substances. In: Polypeptides which affect smooth muscles and blood vessels, pp. 199–209. Ed. by M. Schachter. Oxford 1960.Google Scholar
  221. Werle, E., Berek, U.: Über Kallidin. Biochem. Z. 320, 136–145 (1950).Google Scholar
  222. Werle, E., Götze, W., Keppler, A.: Über die Wirkung des Kallikreins auf den isolierten Darm und über eine neue darmkontrahierende Substanz. Biochem. Z. 289, 217–233 (1937).Google Scholar
  223. Werle, E., Grunz, M.: Zur Kenntnis der darmkontrahierenden, uteruserregenden und blutdrucksenkenden Substanz Dk. Biochem. Z. 301, 429–436 (1939).Google Scholar
  224. Werle, E., Kehl, R., Koebke, K.: Über Trypsin, Chymotrypsin, Kallidin und Bradykinin. Biochem. Z. 321, 213–220 (1950).PubMedGoogle Scholar
  225. Werle, E., Vogel, R., Göldel, L.F.: Über ein blutdrucksteigerndes Prinzip in Extrakten aus der Glandula submaxillaries der weißen Maus. Arch. exp. Path. Pharmakol. 230, 236–244 (1957).Google Scholar
  226. Wernze, H., Fujii, J.: Hepatische Inaktivierung und pressorische Wirkung von Angiotensin. Z. ges. exp. Med. 140, 128–135 (1966).Google Scholar
  227. Wernze, H., Hosoda, S., Schölkens, B.: Zur vasopressorischen Wirkung und Inaktivierung von Angiotensin bei essentieller und renaler sowie experimenteller Hypertonie. Arch. Klin. Med. 214, 286–305 (1968).PubMedGoogle Scholar
  228. Wolf, R.L., Mendlowttz, M., Gitlow, S.E., Naftchi, N.: The metabolism of angiotensin II. Circulat. Res. 11, 195–208 (1962).PubMedGoogle Scholar
  229. Wood, J.E.: Genetic control of neutralization of angiotensin and its relationship to essential hypertension. Circulation 25, 225–230 (1962).PubMedGoogle Scholar
  230. Yamafuji, K., Carrara, M.C.: Studies on the kininase activity of rabbit polymorphonuclear leucocytes. Fed. Proc. 27, 533 (1968).Google Scholar
  231. Yang, H.Y.T., Erdös, E.G.: Second kininase in human blood plasma. Nature (Lond.) 215, 1402–1403 (1967).Google Scholar
  232. Yang, H.Y.T., Erdös, E.G.: Angiotensinase C, characterization and chemical assay. Fourth International Congress on Pharmacology Abstracts, p. 217. Basel 1969a.Google Scholar
  233. Yang, H.Y.T., Erdös, E.G.: Fluorometric assay of angiotensinase C activity. Pharmacologist 11, 217 (1969b).Google Scholar
  234. Yang, H.Y.T., Erdös, E.G., Levin, Y.: A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim. biophys. Acta (Amst.) 214, 374–376 (1970d).Google Scholar
  235. Yang, H.Y.T., Erdös, E.G., Levin, Y.: Characterization of a dipeptide hydrolase. (Kininase II; Angiotensin I converting enzyme). J. Pharmacol. exp. Ther. (in press) (1970e).Google Scholar
  236. Yang, H.Y.T., Erdös, E.G., Chiang, T.S.: New enzymatic route for the inactivation of angiotensin. Nature (Lond.) 218, 1224–1226 (1968).Google Scholar
  237. Yang, H.Y.T., Erdös, E.G., Jenssen, T.A., Rodgers, J.G.: Characteristics of an enzyme that inactivates angiotensin II (angiotensinase C). Biochem. Pharmacol. 19, 1201 (1970a).Google Scholar
  238. Yang, H.Y.T., Erdös, E.G., Jenssen, T.A., Levin, Y.: Characterization of an angiotensin I converting enzyme. Fed. Proc. (in press) (1970c).Google Scholar
  239. Yang, H.Y.T., Jenssen, T.A., Erdös, E.G.: Conversion of angiotensin I by a kininase preparation. Clin. Res. 18, 88 (1970b).Google Scholar
  240. Yman, L., Kulling, B.: An aminopeptidase from human serum specific for hydrolysis of α-L-dicarboxylic amino acid residues. I. Purification from retroplacental serum by preparative polyacrylamide-gel electrophoresis. Acta Pharm. Suecica 6, 561–568 (1969).Google Scholar
  241. Yman, L., Kulltng, B., Barth, T.: An aminopeptidase from human serum specific for hydrolysis of α-L-dicarboxylic amino acid residues. II. Some properties and its relationship to the serum angiotensinase activity. Acta Pharm. Suecica 6, 569–578 (1969).Google Scholar
  242. Zachariae, H., Malmquist, J., Oates, J.A.: Kininase in human polymorphonuclear leukocytes. Life Sci. 5, 2347–2355 (1966).PubMedGoogle Scholar
  243. Zuber, H.: Purification and properties of a new carboxypeptidase from citrus fruit. Nature (Lond.) 201, 613 (1964).Google Scholar
  244. Zuber, H.: Observations on the use of enzymes in the analysis of peptides. In: Peptides, p. 189. Ed. by L. Zervas. Oxford: Pergamon Press 1966.Google Scholar
  245. Zuber, H., Jaques, R.: Isolierung von Bradykinin aus Rinderplasma nach Einwirkung von Schlangengift (Bothrops jararaca). Helv. chim. Acta 43, 1128–1130 (1960).Google Scholar
  246. Zwanzig, M., Oelkers, W.: Untersuchungen über die pH-Abhängigkeit, die Hemmbarkeit und Reaktivierbarkeit von Angiotensin II und Angiotensin II-Amid spaltenden Enzymen des menschlichen Plasmas. Z. klin. Chem. u. klin Biochem. 7, 253–258 (1969).Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1971

Authors and Affiliations

  • E. G. Erdös

There are no affiliations available

Personalised recommendations